Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 360

1.

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy of Non-muscle Invasive Bladder Cancer.

Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MA, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA.

J Urol. 2019 Dec 10:101097JU0000000000000688. doi: 10.1097/JU.0000000000000688. [Epub ahead of print]

PMID:
31821066
2.

Reply by Authors.

Chappidi MR, Stimson CJ, Kates M, Odisho AY, Bivalacqua TJ.

J Urol. 2019 Nov 26:101097JU000000000000052203. doi: 10.1097/JU.0000000000000522.03. [Epub ahead of print] No abstract available.

PMID:
31769720
3.

Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure.

Becker REN, Kates MR, Bivalacqua TJ.

Urol Clin North Am. 2020 Feb;47(1):15-21. doi: 10.1016/j.ucl.2019.09.004. Review.

PMID:
31757296
4.

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.

Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ.

Clin Cancer Res. 2019 Nov 11. doi: 10.1158/1078-0432.CCR-19-1920. [Epub ahead of print]

PMID:
31712383
5.

Evaluation of Incisional Negative Pressure Wound Therapy in the Prevention of Surgical Site Occurrences After Radical Cystectomy: A New Addition to Enhanced Recovery After Surgery Protocol.

Joice GA, Tema G, Semerjian A, Gupta M, Bell M, Walker J, Kates M, Bivalacqua TJ.

Eur Urol Focus. 2019 Nov 5. pii: S2405-4569(19)30292-5. doi: 10.1016/j.euf.2019.09.016. [Epub ahead of print]

PMID:
31704281
6.

Total Penis, Scrotum, and Lower Abdominal Wall Transplantation.

Redett RJ 3rd, Etra JW, Brandacher G, Burnett AL, Tuffaha SH, Sacks JM, Shores JT, Bivalacqua TJ, Bonawitz S, Cooney CM, Coon D, Pustavoitau A, Rizkalla NA, Jackson AM, Javia V, Fidder SAJ, Davis-Sproul J, Brennan DC, Sander IB, Shoham S, Sopko NA, Lee WPA, Cooney DS.

N Engl J Med. 2019 Nov 7;381(19):1876-1878. doi: 10.1056/NEJMc1907956. No abstract available.

PMID:
31693813
7.

The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.

Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC.

Urol Oncol. 2020 Jan;38(1):3.e17-3.e27. doi: 10.1016/j.urolonc.2019.09.023. Epub 2019 Oct 31.

PMID:
31676278
8.

Impact of spheroid culture on molecular and functional characteristics of bladder cancer cell lines.

Yoshida T, Sopko NA, Kates M, Liu X, Joice G, Mcconkey DJ, Bivalacqua TJ.

Oncol Lett. 2019 Nov;18(5):4923-4929. doi: 10.3892/ol.2019.10786. Epub 2019 Aug 29.

9.

Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.

Chalfin HJ, Glavaris SA, Gorin MA, Kates MR, Fong MH, Dong L, Matoso A, Bivalacqua TJ, Johnson MH, Pienta KJ, Hahn NM, McConkey DJ.

Eur Urol Oncol. 2019 Sep 25. pii: S2588-9311(19)30130-0. doi: 10.1016/j.euo.2019.08.004. [Epub ahead of print]

PMID:
31563523
10.

A Nationally Representative Study of Nonindex Hospital Readmissions following Radical Prostatectomy: Implications for Bundled Payment Models.

Chappidi MR, Stimson CJ, Kates M, Odisho AY, Bivalacqua TJ.

J Urol. 2019 Sep 3:101097JU0000000000000522. doi: 10.1097/JU.0000000000000522. [Epub ahead of print]

PMID:
31479405
11.

An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.

Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ, Sankin A, Kates M.

Urol Oncol. 2020 Feb;38(2):40.e17-40.e24. doi: 10.1016/j.urolonc.2019.07.022. Epub 2019 Aug 28.

PMID:
31473090
12.

Penile Allotransplantation: Pushing the Limits.

Hawksworth DJ, Cooney DS, Burnett AL, Bivalacqua TJ, Redett RJ.

Eur Urol Focus. 2019 Jul;5(4):533-535. doi: 10.1016/j.euf.2019.08.004. Epub 2019 Aug 23.

PMID:
31447389
13.

Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer.

Joice GA, Bivalacqua TJ, Kates M.

Nat Rev Urol. 2019 Oct;16(10):599-612. doi: 10.1038/s41585-019-0220-4. Epub 2019 Aug 21. Review.

PMID:
31434998
14.

Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.

Kates M, Nirschl TR, Baras AS, Sopko NA, Hahn NM, Su X, Zhang J, Kochel CM, Choi W, McConkey DJ, Drake CG, Bivalacqua TJ.

Eur Urol Oncol. 2019 Feb 26. pii: S2588-9311(19)30025-2. doi: 10.1016/j.euo.2019.01.017. [Epub ahead of print]

PMID:
31411999
15.

Spotlight on Sexual Medicine: Advances and Issues of Debate.

Bivalacqua TJ.

Eur Urol Focus. 2019 Jul;5(4):525. doi: 10.1016/j.euf.2019.07.006. Epub 2019 Aug 9. No abstract available.

PMID:
31405620
16.

Predictive biomarkers for drug response in bladder cancer.

Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ.

Int J Urol. 2019 Nov;26(11):1044-1053. doi: 10.1111/iju.14082. Epub 2019 Aug 1. Review.

PMID:
31370109
17.

Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer.

Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ, Sankin A, Kates M.

Urol Oncol. 2020 Jan;38(1):5.e9-5.e16. doi: 10.1016/j.urolonc.2019.05.018. Epub 2019 Jun 27.

PMID:
31255541
18.

Regenerative and engineered options for urethroplasty.

Pederzoli F, Joice G, Salonia A, Bivalacqua TJ, Sopko NA.

Nat Rev Urol. 2019 Aug;16(8):453-464. doi: 10.1038/s41585-019-0198-y. Epub 2019 Jun 6. Review.

PMID:
31171866
19.

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA.

Eur Urol. 2019 Aug;76(2):200-206. doi: 10.1016/j.eururo.2019.04.036. Epub 2019 May 12.

PMID:
31092337
20.

Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.

Pederzoli F, Murati Amador B, Samarska I, Lombardo KA, Kates M, Bivalacqua TJ, Matoso A.

Hum Pathol. 2019 Aug;90:1-7. doi: 10.1016/j.humpath.2019.04.018. Epub 2019 May 6.

PMID:
31071342
21.

Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor.

Hassan O, Murati Amador B, Lombardo KA, Salles D, Cuello F, Marwaha AS, Daniels MJ, Kates M, Bivalacqua TJ, Matoso A.

World J Urol. 2019 Apr 27. doi: 10.1007/s00345-019-02782-y. [Epub ahead of print]

PMID:
31030230
22.

Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.

Eich ML, Rodriguez Pena MDC, Springer SU, Taheri D, Tregnago AC, Salles DC, Bezerra SM, Cunha IW, Fujita K, Ertoy D, Bivalacqua TJ, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Netto GJ.

Mod Pathol. 2019 Oct;32(10):1544-1550. doi: 10.1038/s41379-019-0276-y. Epub 2019 Apr 25.

23.

Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.

Eich ML, Chaux A, Guner G, Taheri D, Mendoza Rodriguez MA, Rodriguez Peña MDC, Baras AS, Hahn NM, Drake C, Sharma R, Bivalacqua TJ, Rezaei K, Netto GJ.

Hum Pathol. 2019 Jul;89:24-32. doi: 10.1016/j.humpath.2019.04.003. Epub 2019 Apr 24.

PMID:
31026471
24.

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.

Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.

Nat Rev Urol. 2019 Jun;16(6):377-386. doi: 10.1038/s41585-019-0184-4. Review.

PMID:
31019310
25.

Intratunical injection of autologous adipose stromal vascular fraction reduces collagen III expression in a rat model of chronic penile fibrosis.

Hakim L, Fiorenzo S, Hedlund P, Montorsi F, Bivalacqua TJ, De Ridder D, Weyne E, Ralph D, Garaffa G, Muneer A, Joniau S, Albersen M, Castiglione F; Trauma and Reconstructive Urology Working Party of the European Association of Urology (EAU) Young Academic Urologists (YAU).

Int J Impot Res. 2019 Apr 15. doi: 10.1038/s41443-019-0136-9. [Epub ahead of print]

PMID:
30988428
26.

Molecular Characterization of Neuroendocrine-like Bladder Cancer.

Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC.

Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5.

PMID:
30952638
27.

In Reply.

Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR.

Stem Cells Transl Med. 2019 Jul;8(7):739-740. doi: 10.1002/sctm.19-0068. Epub 2019 Mar 29. No abstract available.

28.

A Systematic Review on Ischemic Priapism and Immediate Implantation: Do We Need More Data?

Capece M, La Rocca R, Mirone V, Bivalacqua TJ, Castiglione F, Albersen M, Ralph DJ, Muneer A, Garaffa G.

Sex Med Rev. 2019 Jul;7(3):530-534. doi: 10.1016/j.sxmr.2018.10.007. Epub 2019 Mar 19. Review.

PMID:
30898595
29.

Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments.

Gupta M, Kates M, Bivalacqua TJ.

Curr Opin Oncol. 2019 May;31(3):183-187. doi: 10.1097/CCO.0000000000000533.

PMID:
30893148
30.

Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer.

Brant A, Daniels M, Chappidi MR, Joice GA, Sopko NA, Matoso A, Bivalacqua TJ, Kates M.

World J Urol. 2019 Dec;37(12):2683-2689. doi: 10.1007/s00345-019-02673-2. Epub 2019 Mar 8.

PMID:
30850856
31.

The Urogenital Epithelium and Corporal Tissues Are the Primary Targets of Rejection in Penile Vascularized Composite Allotransplantation: A New Real-Time Tissue-Based Monitoring System.

Lough DM, Sopko NA, Matsui H, Miller D, Swanson EW, Bluebond-Langner R, Brandacher G, Burnett AL, Bivalacqua TJ, Redett RJ.

Plast Reconstr Surg. 2019 Mar;143(3):534e-544e. doi: 10.1097/PRS.0000000000005377.

PMID:
30817651
32.

A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.

Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR.

Stem Cells Transl Med. 2019 May;8(5):441-449. doi: 10.1002/sctm.18-0230. Epub 2019 Feb 8.

33.

Low-intensity extracorporeal shockwave therapy in the treatment of erectile dysfunction following radical prostatectomy: a critical review.

Usta MF, Gabrielson AT, Bivalacqua TJ.

Int J Impot Res. 2019 May;31(3):231-238. doi: 10.1038/s41443-019-0121-3. Epub 2019 Feb 1. Review.

PMID:
30710107
34.

Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.

Gupta M, Milbar N, Tema G, Pederzoli F, Chappidi M, Kates M, VandenBussche CJ, Bivalacqua TJ.

World J Urol. 2019 Oct;37(10):2051-2058. doi: 10.1007/s00345-018-02624-3. Epub 2019 Jan 23.

PMID:
30671639
35.

Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer.

Gupta N, Bivalacqua TJ, Han M, Gorin MA, Challacombe BJ, Partin AW, Mamawala MK.

BJU Int. 2019 Aug;124(2):268-274. doi: 10.1111/bju.14659. Epub 2019 Jan 27.

PMID:
30570825
36.

Intratunical Injection of Human Adipose Tissue-Derived Stem Cells Restores Collagen III/I Ratio in a Rat Model of Chronic Peyronie's Disease.

Castiglione F, Hedlund P, Weyne E, Hakim L, Montorsi F, Bivalacqua TJ, De Ridder D, Milenkovic U, Ralph D, Garaffa G, Muneer A, Joniau S, Albersen M; Trauma and Reconstructive Urology Working Party of the European Association of Urology Young Academic Urologists.

Sex Med. 2019 Mar;7(1):94-103. doi: 10.1016/j.esxm.2018.09.003. Epub 2018 Nov 30.

37.

Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.

Palsgrove DN, Taheri D, Springer SU, Cowan M, Guner G, Mendoza Rodriguez MA, Rodriguez Pena MDC, Wang Y, Kinde I, Ricardo BFP, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ.

Hum Pathol. 2019 Mar;85:1-9. doi: 10.1016/j.humpath.2018.10.033. Epub 2018 Nov 14.

PMID:
30447301
38.

Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation.

Mitra AP, Fairey AS, Skinner EC, Boorjian SA, Frank I, Schoenberg MP, Bivalacqua TJ, Hyndman ME, Reese AC, Steinberg GD, Large MC, Hulsbergen-van de Kaa CA, Bruins HM, Daneshmand S.

Urol Oncol. 2019 Jan;37(1):48-56. doi: 10.1016/j.urolonc.2018.10.013. Epub 2018 Nov 13.

PMID:
30446450
39.

Correction: Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.

Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, Cohen JD, Taheri D, Silliman N, Schaefer J, Ptak J, Dobbyn L, Papoli M, Kinde I, Afsari B, Tregnago AC, Bezerra SM, VandenBussche C, Fujita K, Ertoy D, Cunha IW, Yu L, Bivalacqua TJ, Grollman AP, Diaz LA, Karchin R, Danilova L, Huang CY, Shun CT, Turesky RJ, Yun BH, Rosenquist TA, Pu YS, Hruban RH, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Dickman KG, Netto GJ.

Elife. 2018 Nov 12;7. pii: e43237. doi: 10.7554/eLife.43237.

40.

CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer.

Ooki A, VandenBussche CJ, Kates M, Hahn NM, Matoso A, McConkey DJ, Bivalacqua TJ, Hoque MO.

Br J Cancer. 2018 Oct;119(8):961-970. doi: 10.1038/s41416-018-0291-7. Epub 2018 Oct 17.

41.

Intratunical injection of stromal vascular fraction prevents fibrosis in a rat model of Peyronie's disease.

Castiglione F, Hedlund P, Weyne E, Hakim L, Montorsi F, Salonia A, Bivalacqua TJ, De Ridder D, Milenkovic U, Ralph D, Garaffa G, Muneer A, Joniau S, Albersen M; Trauma and Reconstructive Urology Working Party of the European Association of Urology (EAU) Young Academic Urologists (YAU).

BJU Int. 2019 Aug;124(2):342-348. doi: 10.1111/bju.14570. Epub 2019 Jun 2.

PMID:
30267556
42.

A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression.

Chakravarthi BVSK, Rodriguez Pena MDC, Agarwal S, Chandrashekar DS, Hodigere Balasubramanya SA, Jabboure FJ, Matoso A, Bivalacqua TJ, Rezaei K, Chaux A, Grizzle WE, Sonpavde G, Gordetsky J, Netto GJ, Varambally S.

Neoplasia. 2018 Sep;20(9):894-904. doi: 10.1016/j.neo.2018.07.006. Epub 2018 Aug 15.

43.

ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.

Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ, Bochner BH, Boormans JL, Chang SS, Domínguez-Escrig JL, McKiernan JM, Dinney C, Godoy G, Kulkarni GS, Mariappan P, O'Donnell MA, Rentsch CA, Shah JB, Solsona E, Svatek RS, van der Heijden AG, van Valenberg FJP, Kassouf W.

World J Urol. 2019 Jan;37(1):51-60. doi: 10.1007/s00345-018-2438-9. Epub 2018 Aug 14. Review.

PMID:
30109483
44.

Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease.

Weyne E, Dewulf K, Deruyer Y, Rietjens R, Everaerts W, Bivalacqua TJ, De Ridder D, Van der Aa F, Albersen M.

Neurourol Urodyn. 2018 Jun;37(5):1594-1604. doi: 10.1002/nau.23517. Epub 2018 Feb 7.

PMID:
30105760
45.

Editorial Comment.

Kates M, Bivalacqua TJ.

J Urol. 2018 Nov;200(5):1011-1012. doi: 10.1016/j.juro.2018.05.157. Epub 2018 Jul 29. No abstract available.

PMID:
30063891
46.

Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter?

Joice GA, Chappidi MR, Patel HD, Kates M, Sopko NA, Stimson CJ, Pierorazio PM, Bivalacqua TJ.

BJU Int. 2018 Dec;122(6):1016-1024. doi: 10.1111/bju.14448. Epub 2018 Jul 26.

47.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC.

World J Urol. 2019 Jan;37(1):165-172. doi: 10.1007/s00345-018-2361-0. Epub 2018 Jun 7.

PMID:
29882105
48.

Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry.

Daneshmand S, Bazargani ST, Bivalacqua TJ, Holzbeierlein JM, Willard B, Taylor JM, Liao JC, Pohar K, Tierney J, Konety B; Blue Light Cystoscopy with Cysview Registry Group.

Urol Oncol. 2018 Aug;36(8):361.e1-361.e6. doi: 10.1016/j.urolonc.2018.04.013. Epub 2018 May 30.

49.

Organoid culture of bladder cancer cells.

Yoshida T, Singh AK, Bishai WR, McConkey DJ, Bivalacqua TJ.

Investig Clin Urol. 2018 May;59(3):149-151. doi: 10.4111/icu.2018.59.3.149. Epub 2018 Apr 30. No abstract available.

50.

Tissue-Engineered Neo-Urinary Conduit from Decellularized Trachea.

Singh A, Lee D, Jeong H, Yu C, Li J, Fang CH, Sabnekar P, Liu X, Yoshida T, Sopko N, Bivalacqua TJ.

Tissue Eng Part A. 2018 Oct;24(19-20):1456-1467. doi: 10.1089/ten.TEA.2017.0436. Epub 2018 Jun 4.

PMID:
29649957

Supplemental Content

Loading ...
Support Center